List of Sivextro drug patents

Sivextro is owned by Cubist Pharms Llc.

Sivextro contains Tedizolid Phosphate.

Sivextro has a total of 7 drug patents out of which 0 drug patents have expired.

Sivextro was authorised for market use on 20 June, 2014.

Sivextro is available in powder;intravenous dosage forms.

Sivextro can be used as method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria, method of treating bacterial infections.

Drug patent challenges can be filed against Sivextro from June, 2023.

The generics of Sivextro are possible to be released after 31 December, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8420676 CUBIST PHARMS LLC Oxazolidinone derivatives
Feb, 2028

(5 years from now)

US7816379 CUBIST PHARMS LLC Oxazolidinone derivatives
Jun, 2028

(5 years from now)

US10442829 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

US9624250 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

US8426389 CUBIST PHARMS LLC Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Dec, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10065947 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

US9988406 CUBIST PHARMS LLC Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
Feb, 2030

(6 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jun 20, 2019
New Patient Population (NPP) Jun 19, 2023
Generating Antibiotic Incentives Now (GAIN) Jun 20, 2024

Drugs and Companies using TEDIZOLID PHOSPHATE ingredient

NCE-1 date: June, 2023

Market Authorisation Date: 20 June, 2014

Treatment: Method of treating bacterial infections; Method of treating acute bacterial skin and skin structure infections (absssi) caused by designated susceptible bacteria

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in